As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the patient monitoring industry, ...
DexCom (DXCM) faces GLP-1 disruption as it targets non-insulin Type 2 CGM growth. Read here for a detailed invesment analysis ...
Compare the Apple Watch, Samsung Galaxy Watch, and Pixel Watch for blood sugar tracking, CGM alerts, health trends, battery ...
Smartwatches may transform blood sugar tracking, but today’s advances depend on CGMs, AI, and regulated health tech ...
Now, her ongoing alliance with a telehealth company may be signifying a broader shift in US healthcare advertising, ...
The 170-acre northeast-side Indianapolis campus is composed of 21 buildings and serves as one of the company’s two global hubs.
StockStory.org on MSN
Patient monitoring stocks Q1 earnings review: Insulet (NASDAQ:PODD) shines
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...
Six weeks after more than 350 delegates gathered in Galway for EDGE26, Ireland’s Creative Economy Summit, CREW has published ...
Adults in the US who want to measure their blood glucose levels using a wearable sensor will soon be able to buy one over-the-counter (OTC) for the first time. The FDA has cleared Dexcom’s Stelo as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results